Novartis
NVS
Novartis (NVS) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HSBC | Upgraded | Reduce → Hold | $136.00 from $123.00 | Sep 10, 2026 |
| Morgan Stanley | Maintained | Overweight | $170.00 from $143.00 | Mar 26, 2026 |
| Barclays | Upgraded | Underweight → Equal-Weight | — | Jan 6, 2026 |
| JP Morgan | Upgraded | Neutral → Overweight | — | Dec 8, 2025 |
| Jefferies | Initiated Coverage | Hold | — | Oct 27, 2025 |
| Goldman Sachs | Downgraded | Neutral → Sell | $118.00 from $119.00 | Sep 12, 2025 |
| UBS | Downgraded | Buy → Neutral | — | Feb 13, 2025 |
| Erste Group | Downgraded | Buy → Hold | — | Nov 19, 2024 |
| BMO Capital | Maintained | Market Perform | $120.00 from $118.00 | Oct 30, 2024 |
| B of A Securities | Downgraded | Buy → Neutral | $130.00 from $135.00 | Sep 11, 2024 |
| Goldman Sachs | Downgraded | Buy → Neutral | $121.00 from $119.00 | Sep 5, 2024 |
| Jefferies | Downgraded | Buy → Hold | — | Sep 3, 2024 |
| Jefferies | Maintained | Buy | $122.50 from $121.00 | Jul 2, 2024 |
| BMO Capital | Maintained | Market Perform | $116.00 from $114.00 | Apr 24, 2024 |
| BMO Capital | Initiated Coverage | Market Perform | $114.00 | Feb 23, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $114.00 | Jan 23, 2024 |
| Morgan Stanley | Upgraded | Underweight → Equal-Weight | — | Sep 25, 2023 |
Frequently asked questions
What is the latest analyst rating on NVS?
On Sep 10, 2026, HSBC upgraded Novartis to Hold with a price target of $136.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.